Abstract
Pelvic inflammatory disease (PID), one of the most common infections in non-pregnant women of reproductive age, remains an important public health problem. It is associated with major long-term sequelae, including tubal factor infertility, ectopic pregnancy, and chronic pelvic pain. In addition, treatment of acute PID and its complications incurs substantial health care costs. Prevention of these long-term sequelae is dependent upon clinicians having a high index of suspicion in order to make an early diagnosis and development of treatment strategies based on knowledge of the microbiologic etiology of acute PID. It is well accepted that acute PID is a polymicrobic infection. The sexually transmitted organisms, Neisseria gonorrhoeae and Chlamydia trachomatis, are present in many cases and microorganisms comprising the endogenous vaginal and cervical flora are frequently associated with PID. This includes anaerobic and facultative bacteria, similar to those associated with bacterial vaginosis. Genital tract mycoplasmas, most importantly Mycoplasma genitalium, have recently also been implicated as a cause of acute PID. As a consequence, treatment regimens for acute PID should provide broad spectrum coverage that is effective against these microorganisms.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
•• Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR 2010;59(No. RR-12):63–67. Major resource for the treatment of acute PID
Ross J, Judlin P, Niles L. European guideline for the management of pelvic inflammatory disease. Int J STD AIDS. 2007;18:662–6.
Sweet RL. Microbiology. In: Sweet RL, Wiesenfeld HC, editors. Pelvic inflammatory disease. London: Taylor & Francis; 2006. p. 19–48.
• Haggerty CL, Ness RB: Diagnosis and treatment of pelvic inflammatory disease. Women’s Health 2008;4:383–97. Excellent review of the diagnosis and treatment of PID
Smith KJ, Ness RB, Wiesenfeld HC, Roberts MS. Cost-effectiveness of alternative outpatient pelvic inflammatory disease treatment strategies. Sex Transm Dis. 2007;34:960–6.
Sutton MY, Sternberg M, Zaidi A, et al. Trends in pelvic inflammatory disease hospital discharges and ambulatory visits, United States; 1985–2001. Sex Transm Dis. 2005;32:778–84.
Rein DB, Kassler WJ, Irwin KL, Rabiee L. Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing but still substantial. Obstet Gynecol. 2000;95:397–402.
Botte J, Peipert JF. Epidemiology. In: Sweet RL, Wiesenfeld HC, editors. Pelvic inflammatory disease. London: Taylor & Francis; 2006. p. 1–18.
Haggerty CL, Ress RB. Epidemiology, pathogenesis and treatment of pelvic inflammatory disease. Expert Rev Anti Infect Ther. 2006;4:235–47.
•• Westrom L: Effect of acute pelvic inflammatory disease on fertility. Am J Obstet Gynecol 1975;121:707–13. Classic study on impact of PID on reproductive health of women
Westrom L, Josef R, Reynolds G, et al. Pelvic inflammatory disease and fertility. A cohort study of 1844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis. 1992;19:185–92.
Haggerty CL, Shultz R, Ness RB. Lower quality of life among women with chronic pelvic pain after pelvic inflammatory disease. Obstet Gynecol. 2003;102:934–9.
Thurman AR, Soper DE. Sequelae. In: Sweet RL, Wiesenfeld HC, editors. Pelvic inflammatory disease. London: Taylor & Francis; 2006. p. 69–84.
•• Wiesenfeld HC, Hillier SL, Krohn MA, et al.: Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol 2002;100:265–63. Study clearly demonstrates the association of subclinical PID with lower genital tract infection with N. gonorrhoeae, C. trachomatis and BV
Wolner-Hanssen P, Kiviat NB, Holmes KK. Atypical pelvic inflammatory disease: subacute, chronic or subclinical upper genital tract infection in women. In: Holmes KK, Mardh P-A, Sparling PF, et al., editors. Sexually transmitted diseases. New York: McGraw-Hill; 1990. p. 615–20.
Westrom L, Eschenbach DA. Pelvic inflammatory disease. In: Holmes KK, Sparling PF, Mardh P-A, Lemon J, Stamm W, Piot P, Wasserheit JN, editors. Sexually transmitted diseases. New York: McGraw-Hill; 1999. p. 783–809.
Walker CK, Wiesenfeld HC. Antibiotic therapy for acute pelvic inflammatory disease: the 2006 centers for disease control and prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis. 2007;44:S111–22.
Haggerty CL, Ness RB. Newest approaches to treatment of pelvic inflammatory disease: a review of recent randomized trials. Clin Infect Dis. 2007;44:953–60.
•• Sweet RL, Gibbs RS: Pelvic inflammatory disease. In Sweet RL, Gibbs RS Infectious Diseases of the Female Genital Tract. Lippincott, Williams & Wilkins, Philadelphia, 2009, pp 220–44. Very comprehensive review of the epidemiology, pathogenesis, etiology, diagnosis, and treatment of acute PID
Kiviat NB, Wolner-Hanssen P, Eschenbach DA, et al. Endometrial histopathology in patients with culture-proven upper genital tract infection and laparoscopically diagnosed acute salpingitis. Am J Surg Pathol. 1990;14:167–75.
Wiesenfeld HC, Sweet RL, Ness RB, et al. Comparison of acute and subclinical pelvic inflammatory disease. Sex Transm Dis. 2005;32:400–5.
•• Jacobsen L, Westrom L: Objectivized diagnosis of acute pelvic inflammatory disease. Am J Obstet Gynecol 1969;105:1088. Classic study on use of laparoscopy to confirm diagnosis of acute salpingitis
Hager WD, Eschenbach DA, Spence MR, Sweet RL. Criteria for diagnosis and grading of salpingitis. Obstet Gynecol. 1983;61:113–4.
Kahn JG, Walker CK, Washington AE, et al. Diagnosing pelvic inflammatory disease: a comprehensive analysis and considerations for developing a new model. JAMA. 1991;266:2594–604.
Soper DE. Surgical considerations in the diagnosis and treatment of pelvic inflammatory disease. Surg Clin North Am. 1991;71:947–62.
Hemila M, Henriksson L, Ylkorkala O. Serum CRP in the diagnosis of pelvic inflammatory disease. Arch Gynecol Obstet. 1987;241:177–82.
Duk JM, Kauer FM, Fleuren GJ, deBruign HW. Serum CA 125 levels in patients with provisional diagnosis of pelvic inflammatory disease. Clinical and theoretical implications. Acta Obstet Gynecol Scand. 1989;68:637–41.
Mozas J, Castilla JA, Jimena P, et al. Serum CA 125 in the diagnosis of acute pelvic inflammatory disease. Int J Gynaecol Obstet. 1994;44:53–7.
Paavonen J, Mettinen A, Heinonen PK, et al. Serum CA-125 in acute pelvic inflammatory disease. Br J Obstet Gynaecol. 1989;96:574–9.
Moore E, Soper DE. Clinical utility of CA 125 levels in predicting laparoscopically confirmed salpingitis in patients with clinically diagnosed pelvic inflammatory disease. Infect Dis Obstet Gynecol. 1988;6:182–5.
Paavonen J, Critchlow CW, DeRoven T, et al. Biology of cervical inflammation. Am J Obstet Gynecol. 1986;154:556–64.
Peipert JF, Boardman L, Hogan JW, et al. Laboratory evaluation of acute upper genital tract infection. Obstet Gynecol. 1996;87:730–6.
Jaiyeoba O, Soper DE: A practical approach to the diagnosis of pelvic inflammatory disease. Infect Dis Ob Gyn (In Press).
Timor-Tritsch E, Rotten S. Transvaginal ultrasonographic study of the fallopian tube. Obstet Gynecol. 1987;70:424–8.
Tukeva TA, Aronen HJ, Karjalainen PT, et al. MR imaging in pelvic inflammatory disease: comparison with laparoscopy and US. Radiology. 1999;210:209–16.
Eschenbach DA, Buchanan T, Pollock HM, et al. Polymicrobial etiology of acute pelvic inflammatory disease. N Engl J Med. 1975;293:166–71.
Sweet RL, Draper DL, Schachter J, et al. Microbiology and pathogenesis of acute salpingitis as determined by laparoscopy: what is the appropriate site to sample? Am J Obstet Gynecol. 1980;138:985–9.
Sweet RL. Sexually transmitted diseases. Pelvic inflammatory disease and infertility in women. Infect Dis Clin North Am. 1987;1:199–215.
Sweet RL, Schachter J, Robbie MO. Failure of beta-lactam antibiotics to eradicate Chlamydia trachomatis in the endometrium despite apparent clinical cure of acute salpingitis. JAMA. 1983;250:2641–5.
Wasserheit JN, Bell TA, Kiviat NB, et al. Microbial causes of proven pelvic inflammatory disease and efficacy of clindamycin and tobramycin. Ann Int Med. 1986;104:187–93.
Heinonen PK, Teisala K, Punnonen R, et al. Anatomic sites of upper genital tract infection. Obstet Gynecol. 1985;66:384–90.
Paavonen J, Teisala K, Heinonen PK, et al. Microbiological and histopathological findings in acute pelvic inflammatory disease. Brit J Obstet Gynaecol. 1987;94:454–60.
Brunham RC, Binns B, Guijon F, et al. Etiology and outcome of acute pelvic inflammatory disease. J Infect Dis. 1988;158:510–7.
Soper DE, Brockwell NJ, Dalton HP, Johnson D. Observations concerning the microbial etiology of acute salpingitis. Am J Obstet Gynecol. 1994;170:1008–17.
Hillier SL, Kiviat NB, Hawes SE, et al. Role of bacterial vaginosis-associated microorganisms in endometritis. Am J Obstet Gynecol. 1996;175:435–41.
Haggerty CL, Hillier SL, Bass DC, et al. Bacterial vaginosis and anaerobic bacteria are associated with endometritis. CID. 2004;39:990–5.
Cohen CR, Manhart LE, Bukusi EA, et al. Association between Mycoplasma genitalium and acute endometritis. Lancet. 2002;359:765–6.
Simms I, Eastick K, Mallinson H, et al. Association between Mycoplasma genitalium, Chlamydia trachomatis and pelvic inflammatory disease. J Clin Pathol. 2003;56:616–8.
Cohen CR, Mugo NR, Astete SG, et al. Detection of Mycoplasma genitalium in women with laparoscopically diagnosed acute salpingitis. Sex Transm Infect. 2005;81:463–6.
Haggerty CL, Totten PA, Astete SG, et al. Failure of cefoxitin and doxycycline to eradicate endometrial Mycoplasma genitalium and the consequence for clinical cure of pelvic inflammatory disease. Sex Transm Infect. 2008;84:338–42.
• Short VL, Totten PA, Ness RB, et al.: Clinical presentation of Mycoplasma genitalium infection versus Neisseria gonorrhoeae infection among women with pelvic inflammatory disease. Clin Infect Dis 2009;48:41–7. Study identifies that M. genitalium may play an important putative role in the etiology of acute PID
Ness RB, Soper DE, Holley RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) randomized trial. Am J Obstet Gynecol. 2002;186:929–37.
Ness RB, Hillier SL, Kip KE, et al. Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol. 2004;104:761–9.
Korn AP, Bolan G, Padian N, et al. Plasma cell endometritis in women with symptomatic bacterial vaginosis. Obstet Gynecol. 1995;85:387–90.
Peipert JF, Montagno AB, Cooper AS, Sung CJ. Bacterial vaginosis as a risk factor for upper genital tract infection. Am J Obstet Gynecol. 1997;177:1184–7.
Sweet RL. Role of bacterial vaginosis in pelvic inflammatory disease. Clin Infect Dis. 1995;20 Suppl 2:271–5.
Ness RB, Kip KE, Hillier SL, et al. A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am J Epidemiol. 2005;162:585–90.
Hebb JK, Cohen CR, Astete SG, et al. Detection of novel organisms associated with salpingitis, by use of 16S rDNA polymerase chain reaction. J Infect Dis. 2004;190:2109–20.
Hillis SD, Joesoef R, Marchbanks PA, et al. Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility. Am J Obstet Gynecol. 1993;168:1503–9.
Smith J, Ness RB, Wiesenfeld HC, et al. Cost-effectiveness of alternate outpatient pelvic inflammatory disease treatment strategies. Sex Transm Dis. 2007;34:960–6.
Amsden GW. Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic pulmonary conditions. J Antimicro Chemother. 2005;55:10–21.
Patton DL, Sweeney YT, Stamm WE. Significant reduction in inflammatory response in the macaque model of chlamydial pelvic inflammatory disease with azithromycin treatment. JID. 2005;192:129–35.
Bevan CD, Ridgway GL, Rothermel CD. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. J Int Med Res. 2003;31:45–54.
Ness RB, Trautmann G, Richter HE, et al. Effectiveness of treatment strategies of some women with pelvic inflammatory disease: a randomized trial. Obstet Gynecol. 2005;106:573–80.
McGregor JA, Crombleholme WR, Newton E, et al. Randomized comparison of ampicillin-sulbactam to cefoxitin and doxycycline or clindamycin and gentamicin in the treatment of pelvic inflammatory disease or endometritis. Ostet Gynecol. 1994;83:998–1004.
Savaris RF, Teixeira LM, Torres G, et al. Comparing ceftriaxone plus azithromycin or doxycyline for pelvic inflammatory disease, a randomized controlled trial. Obstet Gynecol. 2007;110:53–60.
Yip L, Sweeny PJ, Bock BF. Acute suppurative salpingitis with concomitant intrauterine pregnancy. Am J Emerg Med. 1993;11:476–9.
Blanchard AC, Pastorek 2nd JG, Weeks T. Pelvic inflammatory disease during pregnancy. South Med J. 1987;80:1363–5.
Hemsell DL, Ledger WJ, Martens M, et al. Concerns regarding the centers for disease control’s published guidelines for pelvic inflammatory disease. Clin Infect Dis. 2001;32:103–7.
Korn AP, Landers DV, Green JR, Sweet RL. Pelvic inflammatory disease in human immunodeficiency virus-infected women. Obstet Gynecol. 1993;82:765–8.
Irwin KL, Moorman AC, O’Sullivan MJ, et al. Influence of human immunodeficiency virus infection on pelvic inflammatory disease. Obstet Gynecol. 2000;95:525–34.
Cohen CR, Sinei R, Reilly M, et al. Effect of human immunodeficiency virus type 1 infection upon acute salpingitis: a laparoscopic study. J Infect Dis. 1998;178:1352–8.
Bakusi EA, Cohen CR, Stevens CE, et al. Effects of human immunodeficiency virus 1 infection on microbial origins of pelvic inflammatory disease and on the efficacy of ambulatory oral therapy. Am J Obstet Gynecol. 1999;181:1374–81.
Mugo NR, Kiehlbauch JA, Nguti R, et al. Effect of human immunodeficiency virus-1 infection on treatment outcomes of acute salpingitis. Obstet Gynecol. 2006;107:807–12.
Soderberg G, Lindgren S. Influence of an intrauterine device on the course of acute salpingitis. Contraception. 1981;24:137–43.
Altunyurt S, Demir N, Posaci C. A randomized trial of coil removal prior to treatment of pelvic inflammatory disease. Eur J Obstet Gynecol Reprod Biol. 2003;107:81–4.
Disclosure
Dr. R.L. Sweet has received grant funding from NIH, honoraria from Merck and GSK, and author royalties from Lippincott.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sweet, R.L. Pelvic Inflammatory Disease: Current Concepts of Diagnosis and Management. Curr Infect Dis Rep 14, 194–203 (2012). https://doi.org/10.1007/s11908-012-0243-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11908-012-0243-y